CASI Pharmaceuticals, Inc. (NASDAQ:CASI) Short Interest Update

CASI Pharmaceuticals, Inc. (NASDAQ:CASI) was the recipient of a large increase in short interest in December. As of December 31st, there was short interest totalling 61,000 shares, an increase of 43.5% from the December 15th total of 42,500 shares. Approximately 1.6% of the shares of the stock are short sold. Based on an average trading volume of 45,400 shares, the short-interest ratio is presently 1.3 days.

Hedge Funds Weigh In On CASI Pharmaceuticals

An institutional investor recently raised its position in CASI Pharmaceuticals stock. Renaissance Technologies LLC lifted its stake in shares of CASI Pharmaceuticals, Inc. (NASDAQ:CASI) by 10.9% in the second quarter, according to its most recent filing with the SEC. The fund owned 40,800 shares of the biotechnology company’s stock after acquiring an additional 4,000 shares during the period. Renaissance Technologies LLC owned approximately 0.30% of CASI Pharmaceuticals worth $224,000 as of its most recent SEC filing. 22.23% of the stock is owned by institutional investors.

CASI Pharmaceuticals Stock Performance

Shares of NASDAQ CASI remained flat at $2.54 during midday trading on Wednesday. The stock had a trading volume of 21,199 shares, compared to its average volume of 32,511. The company has a current ratio of 3.20, a quick ratio of 2.32 and a debt-to-equity ratio of 1.38. The firm has a 50-day moving average price of $3.76 and a two-hundred day moving average price of $5.37. The stock has a market capitalization of $39.35 million, a P/E ratio of -1.14 and a beta of 0.62. CASI Pharmaceuticals has a 52 week low of $2.05 and a 52 week high of $8.19.

About CASI Pharmaceuticals

CASI Pharmaceuticals, Inc, a biopharmaceutical company, develops and commercializes therapeutics and pharmaceutical products in the People's Republic of China, the United States, and internationally. It offers EVOMELA, an intravenous formulation of melphalan for use as a conditioning treatment prior to stem cell transplantation, and as a palliative treatment for patients with multiple myeloma.